Turner, Alex J.
Sammon, Cormac
Latimer, Nick
Adamson, Blythe
Beal, Brennan
Subbiah, Vivek
Abrams, Keith R.
Ray, Joshua
Funding for this research was provided by:
F. Hoffmann-La Roche
Yorkshire Cancer Research (S406NL)
Medical Research Council (MR/T025166/1/)
Article History
Accepted: 3 October 2023
First Online: 27 October 2023
Declarations
:
: Putnam PHMR received financial support from F. Hoffmann-La Roche Ltd (Grant S406NL)to prepare this article and Medical Research Council (Grant MR/T025166/1/).
: Authors employed by Putnam PHMR (Alex J. Turner; Cormac Sammon) received financial support from F. Hoffmann-La Roche Ltd to prepare this manuscript. Through employment with Putnam PHMR and other consultancies, Alex J. Turner has also received funding for other real-world evidence projects from F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb and BioNTech, and Cormac Sammon has received funding for other real-world evidence projects from F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, BioNTech, Vifor Pharma, Pfizer, Angelini, Immunocore and Stemline. Joshua Ray is an employee of F. Hoffmann-La Roche Ltd, who funded the work. Blythe Adamson and Brennan Beal are employees of Flatiron Health, which is an independent subsidiary of Roche. Keith R. Abrams is a member of the National Institute for Health and Care Excellence Diagnostics Advisory Committee. He has acted as a paid consultant, providing unrelated methodological and strategic advice to the pharmaceutical and life sciences industry (including Roche), as well as to the UK Department of Health and Social Care/National Institute for Health and Care Excellence, and has received unrelated research funding from the Association of the British Pharmaceutical Industry, European Federation of Pharmaceutical Industries and Associations, Pfizer, Sanofi and Swiss Precision Diagnostics. He has also received course fees from Association of the British Pharmaceutical Industry and is a Partner/Director of Visible Analytics Limited, which undertakes projects for Roche. Nick Latimer has received consultancy fees from Daiichi Sankyo, unrelated to the submitted work. He received support from Roche to travel to the ISPOR conference to present in a session that contributed to the conception of the submitted paper. Nick Latimer’s institutions have received funding from Bristol-Myers Squibb, Merck, Sharpe and Dohme, and Vertex for projects that Nick Latimer has worked on. Vivek Subbiah reports consultancy/advisory board participation for Jazz Pharmaceuticals, Loxo Oncology/Eli Lilly, Relay Therapeutics, Pfizer, Roche, ABBVIE, Novartis, Bayer, Aadi biosciences, Illumina, Labcorp and Foundation Medicine. Education: Clinical Care Options, LLC. Nick Latimer is supported by Yorkshire Cancer Research (Award reference number S406NL). Keith R. Abrams is a National Institute for Health and Care Research Senior Investigator Emeritus and is partially supported by the Medical Research Council (Award reference number MR/T025166/1/).
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: Not applicable.
: AJT: Concept and design; drafting of the manuscript. CS: Concept and design; critical revision of the paper for important intellectual content; supervision. NL: Concept and design; critical revision of the paper for important intellectual content. BA: Concept and design; critical revision of the paper for important intellectual content. BB: Concept and design; critical revision of the paper for important intellectual content. VS: Concept and design; critical revision of the paper for important intellectual content. KRA: Concept and design; critical revision of the paper for important intellectual content. JR: Concept and design; critical revision of the paper for important intellectual content; obtaining funding; supervision.